Private Equity investor Apposite Capital acquires Ticino based 1MED

Over 40% of clinical development is currently outsourced, as medical device and pharmaceutical companies seek to reduce their R&D expenditure and face an increasingly more complex regulatory environment. 1MED, based in Agno close to Lugano and founded in 2014, operates in this fast growing market.

The company is a specialist Contract Research Organisation (CRO) that supports the commercialisation of new medical technologies and products by providing regulatory strategy, clinical trial management and quality assurance services across a broad range of therapeutic areas and product types. It is recognised as a reliable outsourced with a 100% product approval rate to date. The company clients base consists primarily of European medical device and pharma companies.

Last week, Apposite Capital, the London-based healthcare specialist private equity investor, announced that it has acquired 1MED. Enrico Perfler, founder and CEO of 1MED will remain a significant shareholder. He commented: “Today opens a new chapter in 1MED’s growth plans. We are very excited by the backing of Apposite Capital. Apposite’s healthcare expertise and international network will be instrumental as we grow to the next phase and seek to expand our service offering and broaden our customer base.”

The investment was led for Apposite Capital by David Porter, Anne-Laure Meynier, Lauren Edison and Christian Schenk. In conjunction with its investment in 1MED, Apposite has introduced Professor John Lyon, a seasoned CRO executive and entrepreneur who will join the Board of Directors as Chair. Additionally, Apposite has introduced Peter Ellingworth, a leading medtech regulatory expert and CEO of the UK Healthtech industry association, ABHI, who will join the Board as a Non-Executive Director. David Porter and Anne-Laure Meynier will also join the Board.

(Press release / SK)